Brief: Evoke Pharma & Eversana Announce Statistically Significant Improvement In Patient Outcomes For Glp-1 Users With Diabetic Gastroparesis Using Gimoti®
28/10/2024 11:57
Oct 28 (Reuters) - Evoke Pharma Inc EVOK.O :
* EVOKE PHARMA & EVERSANA ANNOUNCE STATISTICALLY SIGNIFICANT
IMPROVEMENT IN PATIENT OUTCOMES FOR GLP-1 USERS WITH DIABETIC
GASTROPARESIS USING GIMOTI®
Source text: ID:nGNX46h9Fv
Further company coverage: EVOK.O
((Reuters.Briefs@thomsonreuters.com))
Recent news on Evoke Pharma
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Evoke Pharma Q3 sales rise 61%, expects QOL Medical acquisition to close in Q4 2025
Brief: Evoke Pharma Enters Into Definitive Agreement To Be Acquired By QOL Medical
Evoke Pharma Inc reports results for the quarter ended June 30 - Earnings Summary